187 related articles for article (PubMed ID: 37869095)
1. Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system.
Gui X; Zhao J; Ding L; Chai J; Lai H; Cai Y; Luo S; Zeng Y; Wu W; Chen H; Yao H; Wang Y
Front Oncol; 2023; 13():1276976. PubMed ID: 37869095
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
3. Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System.
Li X; Zhang L; Hu S; Liu D; Hu B; Ran J; Lin X; Mao W; Hu J
Clin Pharmacol Ther; 2024 Feb; 115(2):256-268. PubMed ID: 37994531
[TBL] [Abstract][Full Text] [Related]
4. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
Jiang A; Wei C; Zhu W; Wu F; Wu B
Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
[TBL] [Abstract][Full Text] [Related]
5. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
[TBL] [Abstract][Full Text] [Related]
6. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
7. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
Kong W; Mao W; Zhang L; Wu Y
Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
[TBL] [Abstract][Full Text] [Related]
8. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
[No Abstract] [Full Text] [Related]
9. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
Zhao D; Zhang W; Liu Y; Yan Z
Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
[TBL] [Abstract][Full Text] [Related]
10. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
11. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
12. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.
Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W
Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087
[TBL] [Abstract][Full Text] [Related]
13. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
14. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
[TBL] [Abstract][Full Text] [Related]
15. Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).
Woods RH
Br J Clin Pharmacol; 2023 Aug; 89(8):2386-2395. PubMed ID: 36321844
[TBL] [Abstract][Full Text] [Related]
16. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database.
Long P; Li S; Pan L; Wang Y; Chen W; Wang X
Front Pharmacol; 2024; 15():1378010. PubMed ID: 38766629
[TBL] [Abstract][Full Text] [Related]
18. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.
Zou F; Cui Z; Lou S; Ou Y; Zhu C; Shu C; Chen J; Zhao R; Wu Z; Wang L; Chen Z; Chen H; Lan Y
Front Pharmacol; 2024; 15():1338902. PubMed ID: 38434706
[No Abstract] [Full Text] [Related]
19. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.
Wang J; Zhang A; Ye M; Zhang C
Front Pharmacol; 2024; 15():1376535. PubMed ID: 38562462
[No Abstract] [Full Text] [Related]
20. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]